Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.…
Rhythm Stock Is Up 32%. Is One Drug Enough?
Rhythm Pharmaceuticals (NASDAQ: RYTM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 414 employees.
The shares were at 112.36 USD on 20 November 2026, up 14.1% over 52 weeks. Its 52-week range is 74.50 USD to 122.20 USD: the price is 8.1% below the high and 50.8% above the low.
Its market capitalisation is 7.79B USD.
Rhythm Pharmaceuticals reports return on equity of -72.8%, an operating margin of -66.7% and revenue up 79.6% year over year.
It holds more cash than debt, a net cash position of 214.76M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 17 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 140.12 USD is 24.7% above the current price. The next earnings report is expected on 25 February 2027.